Premium
Lipocortin‐1 autoantibody concentration in children with inflammatory bowel disease
Author(s) -
BEATTIE R. M.,
GOULDING N. J.,
WALKERSMITH J. A.,
MACDONALD T. T.
Publication year - 1995
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1995.tb00418.x
Subject(s) - medicine , ulcerative colitis , autoantibody , inflammatory bowel disease , antibody , annexin a1 , immunology , inflammation , disease , steroid , crohn's disease , annexin , endocrinology , hormone , flow cytometry
SUMMARY Background : Corticosteroids are widely used to treat children with inflammatory bowel disease although the response is variable, side‐effects are common, and many patients develop a partial or complete steroid resistance. The mechanism underlying these phenomena are unclear. Corticosteroids mediate some of their actions through lipocortin‐l, and the inductic of autoantibodies to lipocortin has been proposed as a possible mechanism by which steroid efficacy is suboptimal in vivo.Patients and methods : We have measured serum lipocortin‐1 antibody concentration by ELISA in 38 children with Crohn's disease, 12 with ulcerative colitis and in 15 controls. Results : IgG and IgA anti‐lipocortin‐1 antibody levels were higher in the Crohn's group than in the ulcerative colitis or control groups. Elevated concentrations did not relate to disease activity, history of steroid therapy or steroid‐responsiveness. Lipocortin IgM antibody status was similar in all three groups. Conclusion : It is therefore unlikely that serum antibodies to lipocortin‐1 have a role in the development of steroid‐resistance in children with inflammatory bowel disease.